Quetiapine Rowex 400 mg Prolonged-Release Tablets

Ország: Írország

Nyelv: angol

Forrás: HPRA (Health Products Regulatory Authority)

Vedd Meg Most

Betegtájékoztató Betegtájékoztató (PIL)
02-05-2020
Termékjellemzők Termékjellemzők (SPC)
01-06-2019

Aktív összetevők:

Quetiapine

Beszerezhető a:

Rowex Ltd

ATC-kód:

N05AH; N05AH04

INN (nemzetközi neve):

Quetiapine

Adagolás:

400 milligram(s)

Gyógyszerészeti forma:

Prolonged-release tablet

Recept típusa:

Product subject to prescription which may not be renewed (A)

Terápiás terület:

Diazepines, oxazepines, thiazepines and oxepines; quetiapine

Engedélyezési státusz:

Not marketed

Engedély dátuma:

2012-10-05

Betegtájékoztató

                                PACKAGE LEAFLET: INFORMATION FOR THE USER
QUETIAPINE ROWEX 200 MG PROLONGED-RELEASE TABLETS
QUETIAPINE ROWEX 300 MG PROLONGED-RELEASE TABLETS
QUETIAPINE ROWEX 400 MG PROLONGED-RELEASE TABLETS
Quetiapine
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor, pharmacist or
nurse.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them, even
if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor, pharmacist or nurse.
This includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1. What Quetiapine Rowex is and what it is used for
2. What you need to know before you take Quetiapine Rowex
3. How to take
Quetiapine Rowex
4. Possible side effects
5. How to store Quetiapine Rowex
6. Contents of the pack and other information
1.
WHAT QUETIAPINE ROWEX IS AND WHAT IT IS USED FOR
Quetiapine Rowex contains the active substance quetiapine. This
belongs to a group of medicines
called anti-psychotics. Quetiapine Rowex can be used to treat several
illnesses, such as:
•
Schizophrenia: where you may hear or feel things that are not there,
believe things that are not
true or feel unusually suspicious, anxious, confused, guilty, tense or
depressed.
•
Mania: where you may feel very excited, elated, agitated, enthusiastic
or hyperactive or have
poor judgment including being aggressive or disruptive.
•
Bipolar depression and major depressive episodes in major depressive
disorder: where you feel
sad. You may find that you feel depressed, feel guilty, lack energy,
lose your appetite or can’t
sleep.
When Quetiapine Rowex is being taken to treat major depressive
episodes in major depressive
disorder, it will be taken in addition to another drug being used to
treat this illness.
Your doctor may continue to prescribe
Quetiapine Rowex ev
                                
                                Olvassa el a teljes dokumentumot
                                
                            

Termékjellemzők

                                Health Products Regulatory Authority
31 May 2019
CRN008QGS
Page 1 of 19
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Quetiapine Rowex 400 mg Prolonged-Release Tablets
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each Prolonged Release Tablet contains 400 mg Quetiapine (as
Quetiapine fumarate)
Excipients with known effects: 81.40 mg Lactose monohydrate and per
tablet
For the full list of Excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Prolonged-Release Tablet
White coloured, round shaped, biconvex, film coated tablets debossed
with ‘I4’ on one side and plain on other.
Diameter of the tablet 12.82 ± 0.2 mm.
4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
Quetiapine prolonged release is indicated for:
● treatment of schizophrenia
● treatment of bipolar disorder:
- For the treatment of moderate to severe manic episodes in bipolar
disorder
- For the treatment of major depressive episodes in bipolar disorder
- For the prevention of recurrence of manic or depressed episodes in
patients with bipolar disorder who previously responded
to quetiapine treatment.
● add-on treatment of major depressive episodes in patients with
Major Depressive Disorder (MDD) who have had sub-optimal
response to antidepressant monotherapy (see section 5.1). Prior to
initiating treatment, clinicians should consider the safety
profile of quetiapine prolonged release (see section 4.4).
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
Posology
Different dosing schedules exist for each indication. It must
therefore be ensured that patients receive clear information on the
appropriate dosage for their condition.
ADULTS:
FOR THE TREATMENT OF SCHIZOPHRENIA AND MODERATE TO SEVERE MANIC
EPISODES IN BIPOLAR DISORDER
Quetiapine prolonged release should be administrated at least one hour
before a meal. The daily dose at the start of therapy is
300 mg on Day 1 and 600 mg on Day 2. The recommended daily dose is 600
mg, however if clinically justified the dose may be
increased to 800 mg daily. The dose should be adjusted within th
                                
                                Olvassa el a teljes dokumentumot
                                
                            

A termékkel kapcsolatos riasztások keresése